- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03280849
Chitosan Scaffold for Sellar Floor Repair in Endoscopic Endonasal Transsphenoidal Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction This case describe the use of a novel bilaminar chitosan scaffold in the repair of the sellar floor after an endoscopic endonasal transsphenoidal surgery for a suspected hipofisary macroadenoma, the use of chitosan as a scaffold has been described in several preclinical studies and tested in tissue bioengineering of bone, neural tissue and soft tissue, in the case of bone tissue, several studies demonstrated its potential due to its biocompatibility, osteinductive and osteoconductive features, but there is a lack of clinical trials demonstrating this characteristics in the clinical setting. One of the most common complications for the neurosurgeons after an endoscopic endonasal transsphenoidal surgery is the CSF leak, depending on the technique and the reconstruction used for the sellar floor this complication could be presented from 5% to 75%of the cases, leading to complications such infections and pneumoencephalus, representing a great risk for comorbidities, longer recovery times and hospital costs, due to this challenges in the repair of the sellar floor,the investigators intent to approach the problematic with a chitosan scaffold for its characteristics in bone regeneration. The setting of a bioactive membrane in the defect of the surgery could be useful for a stronger and more suitable closure of the sellar floor.
Case description A 65 years old female participant, right handed, came to the neurosurgery consultation with progressive bilateral visual loss in her temporal fields, with predominance in the left eye over 10 months, two weeks before her admission the participant reported a sudden loss of consciousness, prompting her to go to the hospital. In her clinical examination, the participant was alert and oriented x3, normal cranial nerves examination except for decrease visual acuity by 20/200 in her left eye, 20/80 in her right eye, bitemporal hemianopia and mild primary athropy of the optic disc in the left eye, the gait and the motor and sensitive examination was normal. The laboratory studies showed a LH: 0.22 and prolactine: 53.7 .In the contrasted preoperative brain MRI, it was found a sellar lesion, hypointense in T1 but hyperintense in T2 signal with enhancing of the periphery after the infusion of gadolinium, the lesion presented extension to the sphenoid sinus, paraselar space without involvement of the carotids and supraselar with displacement of the optic chiasm. The participant underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure. In the postoperative there was not complication and after a few days the participant was discharged with notable clinical improvement, after one month of follow up the participant recovered her visual acuity and the participant did not refer any symptom, the participant underwent a post operative brain MRI, where it is observed a gross total resection and good closure of the sellar floor, without signs of rejection or inflammation in the zone with the chitosan scaffold.
Materials and methods for the bilaminar chitosan scaffold The bilaminar implant is constitute by two types of different structures, one of the membranes presents a flat-smooth structure, the other membrane has a tridimensional-porous structure, each of the physical-chemical characteristics given to the membranes, was in function of the biological effect pretended in the effector tissue.
The two types of membranes, synthetized for the elaboration of the bilaminar implant, were elaborated with biomedical grade chitosan of medium molecular weight with 75-85% of deacetylation in powder presentation from the brand Sigma Aldrich®, U.S.A.
In the case of the membrane with flat-smooth structure, it was synthetized from a chitosan solution at 2%, the dissolution medium was diluted acetic acid (Sigma Aldrich®, U.S.A); In order to acquired a suitable solubilisation, the mix was set on a magnetic stirrer for 1 hour, posteriorly the solution was brought under the action of a sonicator at 28oc for 2 hours, until the air bubbles formed by the stirrer were completely eliminated.
For the membrane with the tridimensional-porous structure, it was synthetized from a chitosan solution at 4%, the dissolution medium was diluted acetic acid (Sigma Aldrich®, U.S.A); for a suitable solubilisation, the mix was set on a magnetic stirrer for 4 hours, afterward the solution was brought under the action of a sonicator at 28oc for 2 hours, until the air bubbles formed by the stirrer were completely eliminated.
Once the solutions were elaborated, for the synthesis of the two membranes (the flat-smooth and the tridimensional-porous) both were set in a constant quantity of ml/cm2 in a Petri dish, in the case of the flat-smooth membrane, it was brought under a procedure of drying with 98% of humidity loss and for the tridimensional-porous, a procedure of phase separating was termical induced.
When both membranes are already elaborated, it is proceed to synthetize the bilaminar implant, the membranes are combined using a solution of chitosan acetate at 2%, that was distributed uniformly between both membranes to create a sandwich structure, consecutively the ensemble was put in a Petri dish and the cover was set inverted in the superior aspect of petri dish. It was set for drying for 24 hours at room temperature and then it was precipitated in a solution of sodium hydroxide 1N, following the same indications used for each membrane separately.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- Departamento de neurociencias
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male/female patient candidate for an endoscopic endonasal transphenoidal surgery, who need repair of the sellar floor as part of the surgical procedure.
Exclusion Criteria:
- Diabetes, heart diseases, immunological diseases, infectious diseases, bone diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient with bilaminar chitosan implant
A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
|
The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain MRI with and without contrast
Time Frame: 1 day preoperative
|
Axial-coronal-sagittal MRI in T1,T2 signals-measure of the preoperative tumor size
|
1 day preoperative
|
Brain MRI with and without contrast
Time Frame: 1 day postoperative
|
Axial-coronal-sagittal MRI in T1,T2 signals-measure of the postoperative tumor size
|
1 day postoperative
|
Head CT scan
Time Frame: 1 month postoperative
|
Bone window was used to see the repair of bone defect after surgery
|
1 month postoperative
|
Brain MRI with and without contrast
Time Frame: 1 month postoperative
|
Axial-coronal-sagittal MRI in T1,T2 signals-measure of the postoperative tumor
|
1 month postoperative
|
Brain MRI with and without contrast
Time Frame: 6 months postoperative
|
Axial-coronal-sagittal MRI in T1,T2 signals-measure of the postoperative tumor
|
6 months postoperative
|
Brain MRI with and without contrast
Time Frame: 1 year postoperative
|
Axial-coronal-sagittal MRI in T1,T2 signals-measure of the postoperative tumor
|
1 year postoperative
|
Brain MRI with and without contrast
Time Frame: 2 years postoperative
|
Axial-coronal-sagittal MRI in T1,T2 signals-measure of the postoperative tumor
|
2 years postoperative
|
Head CT scan
Time Frame: 6months postoperative
|
Bone window was used to see the repair of bone defect after surgery
|
6months postoperative
|
Head CT scan
Time Frame: 1 year postoperative
|
Bone window was used to see the repair of bone defect after surgery
|
1 year postoperative
|
Head CT scan
Time Frame: 2 years postoperative
|
Bone window was used to see the repair of bone defect after surgery
|
2 years postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual field test
Time Frame: 1 day preoperative, follow up: 1 day postoperative, 15 days postoperative, 1 month postoperative, 6 months postoperative, 1 year postoperative, 2 years postoperative.
|
visual field testing looking for compression of optic chiasm
|
1 day preoperative, follow up: 1 day postoperative, 15 days postoperative, 1 month postoperative, 6 months postoperative, 1 year postoperative, 2 years postoperative.
|
Snellen test
Time Frame: 1 day preoperative, follow up: 1 day postoperative, 15 days postoperative, 1 month postoperative, 6 months postoperative, 1 year postoperative, 2 years postoperative.
|
visual acuity testing
|
1 day preoperative, follow up: 1 day postoperative, 15 days postoperative, 1 month postoperative, 6 months postoperative, 1 year postoperative, 2 years postoperative.
|
Glasgow scale
Time Frame: 1 day preoperative, follow up :1 day postoperative, 15 days postoperative, 1 month postoperative, 6 months postoperative, 1 year postoperative, 2 years postoperative.
|
level of consciousness
|
1 day preoperative, follow up :1 day postoperative, 15 days postoperative, 1 month postoperative, 6 months postoperative, 1 year postoperative, 2 years postoperative.
|
Endocrinological panel
Time Frame: 1 day preoperative, follow up : 1 day postoperative, 15 days postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
evaluation of hipofisary function
|
1 day preoperative, follow up : 1 day postoperative, 15 days postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
Blood cell count
Time Frame: 1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
For evaluation of any inflammatory reaction or infection before or after the procedure
|
1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
acute phase reactans
Time Frame: 1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
For evaluation of any inflammatory reaction or infection before or after the procedure
|
1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
blood electrolytesand
Time Frame: 1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
evaluation of renal function and as requirement for surgery
|
1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
liver function test
Time Frame: 1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
evaluation of liver function and as requirement for surgery
|
1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
coagulation test
Time Frame: 1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
secondary evaluation of liver function, inflammatory reaction or infection before and after the procedure and as requirement for surgery.
|
1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
seric creatinine
Time Frame: 1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
evaluation of renal function and as requirement for surgery
|
1 day preoperative, follow up: 1 day postoperative , 1 month postoperative, 6 months postoperative,1 year postoperative, 2 years postoperative
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Rodrigo Ramos Zuñiga, M.D. PhD, University of Guadalajara
- Principal Investigator: Brenda Vega Ruiz, PhD, University of Guadalajara
- Principal Investigator: Ivan Segura Duran, M.D., University of Guadalajara
Publications and helpful links
General Publications
- Gobin AS, Butler CE, Mathur AB. Repair and regeneration of the abdominal wall musculofascial defect using silk fibroin-chitosan blend. Tissue Eng. 2006 Dec;12(12):3383-94. doi: 10.1089/ten.2006.12.3383.
- Paulo NM, de Brito e Silva MS, Moraes AM, Rodrigues AP, de Menezes LB, Miguel MP, de Lima FG, de Morais Faria A, Lima LM. Use of chitosan membrane associated with polypropylene mesh to prevent peritoneal adhesion in rats. J Biomed Mater Res B Appl Biomater. 2009 Oct;91(1):221-7. doi: 10.1002/jbm.b.31393.
- Udpa N, Iyer SR, Rajoria R, Breyer KE, Valentine H, Singh B, McDonough SP, Brown BN, Bonassar LJ, Gao Y. Effects of chitosan coatings on polypropylene mesh for implantation in a rat abdominal wall model. Tissue Eng Part A. 2013 Dec;19(23-24):2713-23. doi: 10.1089/ten.TEA.2012.0739. Epub 2013 Aug 21.
- Tchemtchoua VT, Atanasova G, Aqil A, Filee P, Garbacki N, Vanhooteghem O, Deroanne C, Noel A, Jerome C, Nusgens B, Poumay Y, Colige A. Development of a chitosan nanofibrillar scaffold for skin repair and regeneration. Biomacromolecules. 2011 Sep 12;12(9):3194-204. doi: 10.1021/bm200680q. Epub 2011 Aug 1.
- Stippler M, Gardner PA, Snyderman CH, Carrau RL, Prevedello DM, Kassam AB. Endoscopic endonasal approach for clival chordomas. Neurosurgery. 2009 Feb;64(2):268-77; discussion 277-8. doi: 10.1227/01.NEU.0000338071.01241.E2.
- Gardner PA, Kassam AB, Snyderman CH, Carrau RL, Mintz AH, Grahovac S, Stefko S. Outcomes following endoscopic, expanded endonasal resection of suprasellar craniopharyngiomas: a case series. J Neurosurg. 2008 Jul;109(1):6-16. doi: 10.3171/JNS/2008/109/7/0006.
- Greenfield JP, Anand VK, Kacker A, Seibert MJ, Singh A, Brown SM, Schwartz TH. Endoscopic endonasal transethmoidal transcribriform transfovea ethmoidalis approach to the anterior cranial fossa and skull base. Neurosurgery. 2010 May;66(5):883-92; discussion 892. doi: 10.1227/01.neu.0000368395.82329.c4.
- Gardner PA, Kassam AB, Thomas A, Snyderman CH, Carrau RL, Mintz AH, Prevedello DM. Endoscopic endonasal resection of anterior cranial base meningiomas. Neurosurgery. 2008 Jul;63(1):36-52; discussion 52-4. doi: 10.1227/01.NEU.0000335069.30319.1E.
- Simoes MJ, Gartner A, Shirosaki Y, Gil da Costa RM, Cortez PP, Gartner F, Santos JD, Lopes MA, Geuna S, Varejao AS, Mauricio AC. In vitro and in vivo chitosan membranes testing for peripheral nerve reconstruction. Acta Med Port. 2011 Jan-Feb;24(1):43-52. Epub 2011 Feb 28.
- Meyer C, Stenberg L, Gonzalez-Perez F, Wrobel S, Ronchi G, Udina E, Suganuma S, Geuna S, Navarro X, Dahlin LB, Grothe C, Haastert-Talini K. Chitosan-film enhanced chitosan nerve guides for long-distance regeneration of peripheral nerves. Biomaterials. 2016 Jan;76:33-51. doi: 10.1016/j.biomaterials.2015.10.040. Epub 2015 Oct 21.
- Zhao Y, Wang Y, Gong J, Yang L, Niu C, Ni X, Wang Y, Peng S, Gu X, Sun C, Yang Y. Chitosan degradation products facilitate peripheral nerve regeneration by improving macrophage-constructed microenvironments. Biomaterials. 2017 Jul;134:64-77. doi: 10.1016/j.biomaterials.2017.02.026. Epub 2017 Feb 22.
- Ghasemi Hamidabadi H, Rezvani Z, Nazm Bojnordi M, Shirinzadeh H, Seifalian AM, Joghataei MT, Razaghpour M, Alibakhshi A, Yazdanpanah A, Salimi M, Mozafari M, Urbanska AM, Reis RL, Kundu SC, Gholipourmalekabadi M. Chitosan-Intercalated Montmorillonite/Poly(vinyl alcohol) Nanofibers as a Platform to Guide Neuronlike Differentiation of Human Dental Pulp Stem Cells. ACS Appl Mater Interfaces. 2017 Apr 5;9(13):11392-11404. doi: 10.1021/acsami.6b14283. Epub 2017 Mar 27.
- Rodriguez-Vazquez M, Vega-Ruiz B, Ramos-Zuniga R, Saldana-Koppel DA, Quinones-Olvera LF. Chitosan and Its Potential Use as a Scaffold for Tissue Engineering in Regenerative Medicine. Biomed Res Int. 2015;2015:821279. doi: 10.1155/2015/821279. Epub 2015 Oct 4.
- Sandoval-Sanchez JH, Ramos-Zuniga R, de Anda SL, Lopez-Dellamary F, Gonzalez-Castaneda R, Ramirez-Jaimes Jde L, Jorge-Espinoza G. A new bilayer chitosan scaffolding as a dural substitute: experimental evaluation. World Neurosurg. 2012 Mar-Apr;77(3-4):577-82. doi: 10.1016/j.wneu.2011.07.007. Epub 2011 Nov 7.
- Nawrotek K, Marqueste T, Modrzejewska Z, Zarzycki R, Rusak A, Decherchi P. Thermogelling chitosan lactate hydrogel improves functional recovery after a C2 spinal cord hemisection in rat. J Biomed Mater Res A. 2017 Jul;105(7):2004-2019. doi: 10.1002/jbm.a.36067. Epub 2017 Apr 12.
- Mota J, Yu N, Caridade SG, Luz GM, Gomes ME, Reis RL, Jansen JA, Walboomers XF, Mano JF. Chitosan/bioactive glass nanoparticle composite membranes for periodontal regeneration. Acta Biomater. 2012 Nov;8(11):4173-80. doi: 10.1016/j.actbio.2012.06.040. Epub 2012 Jul 5.
- Azevedo AS, Sa MJ, Fook MV, Neto PI, Sousa OB, Azevedo SS, Teixeira MW, Costa FS, Araujo AL. Use of chitosan and beta-tricalcium phosphate, alone and in combination, for bone healing in rabbits. J Mater Sci Mater Med. 2014 Feb;25(2):481-6. doi: 10.1007/s10856-013-5091-2. Epub 2013 Nov 17.
- Fan J, Park H, Lee MK, Bezouglaia O, Fartash A, Kim J, Aghaloo T, Lee M. Adipose-derived stem cells and BMP-2 delivery in chitosan-based 3D constructs to enhance bone regeneration in a rat mandibular defect model. Tissue Eng Part A. 2014 Aug;20(15-16):2169-79. doi: 10.1089/ten.TEA.2013.0523. Epub 2014 May 9.
- Zhao F, Yin Y, Lu WW, Leong JC, Zhang W, Zhang J, Zhang M, Yao K. Preparation and histological evaluation of biomimetic three-dimensional hydroxyapatite/chitosan-gelatin network composite scaffolds. Biomaterials. 2002 Aug;23(15):3227-34. doi: 10.1016/s0142-9612(02)00077-7.
- Liuyun J, Yubao L, Chengdong X. A novel composite membrane of chitosan-carboxymethyl cellulose polyelectrolyte complex membrane filled with nano-hydroxyapatite I. Preparation and properties. J Mater Sci Mater Med. 2009 Aug;20(8):1645-52. doi: 10.1007/s10856-009-3720-6. Epub 2009 Mar 20.
- Zhang J, Wang C, Wang J, Qu Y, Liu G. In vivo drug release and antibacterial properties of vancomycin loaded hydroxyapatite/chitosan composite. Drug Deliv. 2012 Jun-Jul;19(5):264-9. doi: 10.3109/10717544.2012.704093.
- Pu XM, Yao QQ, Yang Y, Sun ZZ, Zhang QQ. In vitro degradation of three-dimensional chitosan/apatite composite rods prepared via in situ precipitation. Int J Biol Macromol. 2012 Dec;51(5):868-73. doi: 10.1016/j.ijbiomac.2012.07.008. Epub 2012 Jul 16.
- Kim SB, Kim YJ, Yoon TL, Park SA, Cho IH, Kim EJ, Kim IA, Shin JW. The characteristics of a hydroxyapatite-chitosan-PMMA bone cement. Biomaterials. 2004 Nov;25(26):5715-23. doi: 10.1016/j.biomaterials.2004.01.022.
- Teng SH, Lee EJ, Wang P, Shin DS, Kim HE. Three-layered membranes of collagen/hydroxyapatite and chitosan for guided bone regeneration. J Biomed Mater Res B Appl Biomater. 2008 Oct;87(1):132-8. doi: 10.1002/jbm.b.31082.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Cerebrospinal Fluid Leak
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hemostatics
- Coagulants
- Chelating Agents
- Sequestering Agents
- Chitosan
Other Study ID Numbers
- CI.064.2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Csf Leakage
-
Rawalpindi Medical CollegeRecruiting
-
Wuhan Union Hospital, ChinaNot yet recruiting
-
Shanghai Chest HospitalUnknownNSCLC | SBRT | GM-CSFChina
-
Centre Hospitalier Universitaire de BesanconCompletedCSF Circulation Disorder | Foramen; Monro, Obstruction | MriFrance
-
Karolinska University HospitalJansson, Anders, M.D.Completed
-
University of OklahomaRecruitingAir LeakageUnited States
-
Coloplast A/SCompletedClinical Investigation of an Improved Two-piece Stoma Product for People Living With a Stoma (CP343)Stoma Site LeakageUnited States
-
NorthShore University HealthSystemTerminatedStoma Site LeakageUnited States
-
Common SenseCompletedAMNIOTIC FLUID LEAKAGE
Clinical Trials on Implant of bilaminar chitosan scaffold
-
BaermedUnknownLiver Cirrhosis | Chronic Liver Disease | Liver InsufficiencyIndonesia
-
Nourhan M.AlyAlexandria UniversityCompleted
-
Denver Nephrologists, P.C.CM&D Pharma LimitedCompletedChronic Kidney DiseaseUnited States
-
Charite University, Berlin, GermanyTerminatedAcute Coronary Syndrome | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionGermany
-
Caspar WohlfahrtDr Caspar Wohlfahrt; Dr Maria BaltaRecruitingPeriodontitis | Periodontal Diseases | Periodontal Pocket | Periodontal InflammationNorway
-
Universidade do PortoUniversidade Católica PortuguesaCompletedAtopic DermatitisPortugal
-
Cairo UniversityUnknown
-
University of OsloCompletedPeri-implant Mucositis | Periimplantitis
-
R3 Vascular Inc.Cardiovascular Research Foundation, New York; Massachusetts General Physicians...RecruitingPeripheral Arterial Disease | Lower Extremity Claudication | Lower Extremity Ischemia | Atherosclerotic LesionCanada, Italy, Austria
-
Chulalongkorn UniversityCompletedSafety Issues | Pressure SoreThailand